Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nutriband Inc WT (NQ: NTRBW )

2.312 +0.462 (+25.00%)
Streaming Delayed Price Updated: 9:39 AM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 102
Open 2.312
Bid (Size) 1.750 (1)
Ask (Size) 2.030 (1)
Prev. Close 1.850
Today's Range 2.312 - 2.312
52wk Range 1.400 - 6.000
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nutriband to Attend 2023 BIO International Convention
Via ACCESSWIRE
Nutriband Inc. Reports Revenue Up 46% in Fiscal 2023
Via ACCESSWIRE

Performance

YTD
-7.50%
-7.50%
1 Month
+21.07%
+21.07%
3 Month
-17.41%
-17.41%
6 Month
-22.92%
-22.92%
1 Year
-61.39%
-61.39%

More News

Read More
Nutriband Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023
Via ACCESSWIRE
Nutriband With Kindeva Drug Delivery Select Aversa(TM) Fentanyl Abuse Deterrent Formulation for Commercial Scale Manufacturing Process Development
Via ACCESSWIRE
Nutriband Secures $2 Million Line of Credit Financing Facility to be Used for Commercialization of AVERSA(TM) Abuse-Deterrent Transdermal Technology
Via ACCESSWIRE
Nutriband Inc. Commences Trading on Upstream Under NTRB
Via ACCESSWIRE
Nutriband Inc. Will Be the First Company to Dual List on Upstream
Via ACCESSWIRE
Nutriband Approved for Dual Listing on Upstream
Via ACCESSWIRE
Nutriband Inc Joins Webull Corporate Communications Service Platform
Via ACCESSWIRE
Nutriband COO Alan Smith Ph.D. Selected for FDA Center for Research on Complex Generics Stakeholder Expert Committee
Via ACCESSWIRE
Nutriband Inc. to File for Product Distribution Permit in South America with Ecuador's Health Register
Via ACCESSWIRE
Nutriband Inc. to Present at the 2023 Transdermal and Microneedle Conference
Via ACCESSWIRE
Nutriband Inc. to Officially Launch AI Tape brand in Q1 2023
Via ACCESSWIRE
Nutriband Supports Newly Published CDC Opioid Prescribing Guidelines
Via ACCESSWIRE
Nutriband Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
Nutriband Inc. Reports Record Revenue Up 118% YoY in Q3
Via ACCESSWIRE
Nutriband Inc to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022
Via ACCESSWIRE
Nutriband Receives Notice of Issuance from the Canadian Intellectual Property Office for its AVERSA(TM) Abuse Deterrent Transdermal Technology Patent
Via ACCESSWIRE
Nutriband To Manufacture Fleur Marché-Branded CBD Wellness Patches
Via Benzinga
Nutriband Inc. to Manufacture Fleur Marché-branded Wellness Patches Under Exclusive Agreement
Via ACCESSWIRE
Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. on Lymphatic Etanercept Delivery in Rheumatoid Arthritis Patients With Results To Be Presented at the 2022 American College of Rheumatology
Via ACCESSWIRE
Nutriband Inc. Invited to Present at the 2023 Transdermal and Microneedle Conference in London on January 23 and 24
Via ACCESSWIRE
Nutriband With Kindeva Drug Delivery Demonstrate Enhanced Abuse-Deterrent Characteristics for AVERSA(TM) Fentanyl
Via ACCESSWIRE
Nutriband Inc. Announces Application for Dual Listing on Upstream
Via ACCESSWIRE
Nutriband Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.